Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-21
2006-11-21
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S399000
Reexamination Certificate
active
07138374
ABSTRACT:
The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.
REFERENCES:
patent: 4785079 (1988-11-01), Gospodarowicz et al.
patent: 4902782 (1990-02-01), Gospodarowicz et al.
patent: 4956455 (1990-09-01), Esch et al.
patent: 4994559 (1991-02-01), Moscatelli et al.
patent: 5026839 (1991-06-01), Moscatelli et al.
patent: 5130418 (1992-07-01), Thompson
patent: 5132408 (1992-07-01), Baird et al.
patent: 5136025 (1992-08-01), Scheuermann et al.
patent: 5143829 (1992-09-01), Thompson et al.
patent: 5155214 (1992-10-01), Baird et al.
patent: 5191067 (1993-03-01), Lappi et al.
patent: 5206354 (1993-04-01), Seddon et al.
patent: 5217954 (1993-06-01), Foster et al.
patent: 5252718 (1993-10-01), Baid et al.
patent: 5302702 (1994-04-01), Seddon et al.
patent: 5310883 (1994-05-01), Seddon et al.
patent: 5331095 (1994-07-01), Shadle et al.
patent: 5332804 (1994-07-01), Florkiewicz et al.
patent: 5348863 (1994-09-01), Monsan et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5352589 (1994-10-01), Bergonzoni et al.
patent: 5360896 (1994-11-01), Senoo et al.
patent: 5371206 (1994-12-01), Seddon et al.
patent: 5387673 (1995-02-01), Seddon et al.
patent: 5439818 (1995-08-01), Fiddes et al.
patent: 5459250 (1995-10-01), Basilico et al.
patent: 5464774 (1995-11-01), Baird et al.
patent: 5478804 (1995-12-01), Calabresi et al.
patent: 5482929 (1996-01-01), Fukunaga et al.
patent: 5491220 (1996-02-01), Seddon et al.
patent: 5514566 (1996-05-01), Fiddes et al.
patent: 5514652 (1996-05-01), Watanuki et al.
patent: 5576288 (1996-11-01), Lappi et al.
patent: 5604293 (1997-02-01), Fiddes et al.
patent: 5612211 (1997-03-01), Wilson et al.
patent: 5614496 (1997-03-01), Dunstan et al.
patent: 5656598 (1997-08-01), Dunstan et al.
patent: 0 237 966 (1987-09-01), None
patent: 0 281 822 (1988-09-01), None
patent: 0 363 675 (1990-04-01), None
patent: 0 420 222 (1991-04-01), None
patent: 0 510 662 (1992-10-01), None
patent: 0 281 822 (1994-07-01), None
patent: WO 90/02800 (1990-03-01), None
patent: WO 91/09126 (1991-06-01), None
patent: WO 91/14785 (1991-10-01), None
patent: WO 95/08630 (1995-03-01), None
patent: WO 96/22369 (1996-07-01), None
Ago, H. et al., “Crystal Structure of Basic Fibroblast Growth Factor at 1.6 A Resoluton”,J. Biochem, 1991, 110, 360-363.
Arakawa, T. et al., “Characterization of a Cysteine-Free Analog of Recombinant Human Basic Fibroblast Growth Factor”,Biochem. Biophys. Comm., 1989, 161(1), 335-341.
Arakawa, T. et al., “The Importance of Arg40 and 45 in the Mitogenic Activity and Structural Stability of Basic Fibroblast Growth Factor-Effects of Acidic Amino Acid Substitutions”,J. Prot. Chem., 1995, 14(5), 263-274.
Basilico, C. et al., “The FGF Family of Growth Factors and Oncogenes”,Adv. Canc. Res., 1992, 59, 115-165.
Blaber, M. et al., “X-ray Crystal Structure of Human Acidic Fibroblast Growth Factor”,Biochemistry, 1996, 35(7), 2086-2094.
Bowie, J. et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”,Science, 1990, 247, 1306-1310.
Burgess, W.H. et al., “Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-b-Inding Activities by Site-directed Mutagenesis of a Single Lysine Residue”,J. Cell. Biol., 1990, 111, 2129-2138.
Burgess, W.H. et al., “Structure-function Studies of FGF-1: Dissociation and Partial Reconstitution of Certain of its Biological Activites”,Molec. Reprod. Devel., 1994, 39: 56-61.
Cheng, H. et al., “Spinal Cord Repair in Adult Paraplegic Rats: Partial Restoration of Hind Limb Function”,Science, 1996, 275, 510-513.
Copeland, R.A. et al., “The Structure of Human Acidic Fibroblast Growth Factor and Its Interaction with Heparin”,Arch. Biochem. Biophys., 1991, 289(1), 53-61.
Cunningham, et al., “High-Resolution Epitope Mapping of hGH-Receptor Interacting by Scanning Mutagenesis”,Science, Jun. 1989, 244, 1081-1085.
Eriksson, A.E. et al., “Three-Dimensional Structure of Human Basic Fibroblast Growth Factor”,Proc. Natl. Acad. Sci., 1991, 88, 3441-3445.
Eriksson, A.E. et al., “Refinement of the Structure of Human Basic Fibroblast Growth Factor at 1.6 A Resolution and Analysis of Presumed Heparin Binding Sites by Selenate Substitution”,Prot. Natl. Sci., 1993, 2, 1274-1284.
Faham, S. et al., “Heparin Structure and Interactions with Basic Growth Factor”,Science, 1996, 271, 1116-1120.
Fox, G.M. et al., “Production, Biological Activity and Structure of Recombinant Basic Fibroblast Growth Factor and a Analog with Cysteine Replaced by Serine”,J. Biol. Chem., 1988, 263(34), 18452-18458.
Friedman, S. et al., “Mutagenesis of the Nuclear Localization Sequence in FGF-1 Alters Protein Stability but not Mitogenic Activity”,Biochem. Biophys. Res. Comm., 1994, 198(3), 1203-1208.
Harper, J.W. et al., “Reductive Methylation of Lysine Residues in Acidic Fibroblast Growth Factor: Effect on Mitogenic Activity Heparin Affinity”,Biochemistry, 1988, 27, 671-678.
Heath, W.F. et al., “Mutations in the Heparin-Binding Domains of Human Basic Fibroblast Growth Factor Alter its Biological Activity”,Biochemistry, 1991, 30, 5608-5615.
Henderson, B. et al., “Therapeutic Potential f Cytokine Manipulation”,TIPS, 1992, 13, 145-152.
Imamura, T. et al., “Recovery of Mitogenic Activityof a Growth Factor Mutant with a Nuclear Translocation Sequence”,Science, 1990, 249, 1567-1570.
International Search Report for PCT/US99/30534, mailed Sep. 1, 2000.
Issachi, A. et al., “A Mutant of Basic Fibroblast Growth Factor that has Lost the Ability to Stimulate Plasminogen Activator Synthesis in Endothelial Cells”,Ann. NY Acad. Sci., 1991, 638, 369-377.
Isacchi, A. et al., “A Six-Amino Acid Deletion in Basic Fibroblast Growth Factor Dissociates its Mitogenic Activity from its Plasminogen Activator-Inducing Capacity”,Proc. Natl. Acad. Sci, 1991, 88, 2628-2632.
Kusstatscher, S. et al., “Different Molecular Forms of Basic Fibroblast Growth Factor (bFGF) Accelerate Duodenal Ulcer Healing in Rats”,J. Pharmacol. Exp. Ther., 1995, 275, 456-461.
Li, L.Y et al., “Diminished Heparin binding of a Basic Fibroblast Growth Factor Mutant is Associated with Reduced Binding, mitogenesis, Plasminogen Activator and in Vitro Angiogenesis”,Biochemistry, 1994, 33, 10999-11007.
Liszewski, K., “Companies Aim Novel Therapeutic Strategies at Dual Nature of Angigenesis”,Gen. Eng. News, May 1, 1997, 6 pages.
Logan, A. et al., “Transforming Growth Factor-β1 and Basic Fibroblast Growth Factor in the Injured CNS”,TIPS, 1993, 14, 337-343.
Martin, P. “Wound Healing-Aiming for Perfect Skin Regeneration”,Science, 1997, 276, 75-81.
Ornitz, D.M. et al., “FGF Binding and FGF Receptor Activated by Synthetic Heparan-Derived Di-and Trisaccharides”,Science, 1995, 268, 432-436.
Pantoliano, M.W. et al., “Multivalent Ligand-Receptor Binding Interactions in the Fibroblast Growth Factor System Produce a Cooperative Growth Factor and Heparin Mechanism for Receptor Dimerization”,Biochemistry, 1994, 33, 10229-10248.
Presta, M. et al., “Structure-Function Relationship of Basic Fibroblast Growth Factor: Site-Directed Mutagenesis of a Putative Heparin-Binding and Receptor-Binding Region”,Biochem. Biophys. Res. Comm, 1992, 185(3), 10
Pantoliano Michael W.
Sharp Celia M.
Springer Barry A.
3-Dimensional Pharmaceuticals Inc.
Saoud Christine J.
Woodcock & Washburn LLP
LandOfFree
Methods of using analogs of human basic fibroblast growth... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using analogs of human basic fibroblast growth..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using analogs of human basic fibroblast growth... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3706396